FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-31 08:00 |
Final Patient Identified for BEXMAB Phase II Study
|
English | 18.5 KB | ||
| 2024-12-13 08:00 |
Faron’s Financial Calendar for 2025
|
English | 9.9 KB | ||
| 2024-12-10 08:00 |
Faron presents BEXMAB data at ASH Annual Meeting
|
English | 23.8 KB | ||
| 2024-12-02 09:00 |
Interactions with UK Regulatory Authorities
|
English | 18.7 KB | ||
| 2024-11-27 08:00 |
Positive Phase 2 Interim Results from BEXMAB Trial
|
English | 22.9 KB | ||
| 2024-11-11 08:00 |
Targeting Soluble Clever-1 for Autoimmune Diseases
|
English | 15.2 KB | ||
| 2024-11-05 08:00 |
Shareholders’ Nomination Board
|
English | 13.4 KB | ||
| 2024-10-22 08:00 |
Faron’s Capital Markets Day 2024
|
English | 29.7 KB | ||
| 2024-10-07 08:00 |
Faron announces Capital Markets Day
|
English | 17.6 KB | ||
| 2024-08-30 08:00 |
Grant of options
|
English | 34.7 KB | ||
| 2024-08-27 08:00 |
Faron 2024 Half-Year Financial Results
|
English | 178.1 KB | ||
| 2024-08-27 08:00 |
FDA Grants Fast Track Designation for Bexmarilimab
|
English | 17.7 KB | ||
| 2024-08-20 08:00 |
Notice of Half-Year Financial Results
|
English | 16.6 KB | ||
| 2024-08-13 08:00 |
Traumakine Research Collaboration and DoD Grant
|
English | 15.3 KB | ||
| 2024-08-08 08:00 |
Appointment of Chief Financial Officer
|
English | 16.8 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
